Acadia Pharmaceuticals Inc.
19.73USD
-0.5800 (-2.86%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ACAD.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 517.2M | 726.4M | 957.8M | 1.1B | 1.3B | 1.4B |
| Q1 | 115.5M | 118.5M | 205.8M | 244.3M | 268.1M | — |
| Q2 | 134.6M | 165.2M | 242.0M | 264.6M | 308.0M | — |
| Q3 | 130.7M | 211.7M | 250.4M | 278.6M | 332.6M | — |
| Q4 | 136.5M | 231.0M | 259.6M* | 284.0M* | 361.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.34 | -.370 | 1.36 | 2.30 | .595 | .921 |
| Q1 | -.700 | -.270 | .100 | .110 | .020 | — |
| Q2 | -.000 | .010 | .200 | .160 | .180 | — |
| Q3 | -.000 | -.400 | .200 | .420 | .182 | — |
| Q4 | -.260 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .280 |
| .864* |
| 1.61* |
| .210 |
| — |
Debt level and coverage